28 completed. 28 Phase 3, 1 Phase 2.
By phase and status
Follow Revlimid: new trials by email Literature Review of Revlimid trials Research Report on Revlimid
Trials (filtered) newest first · largest first
All 28 trials
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|
Testing the Addition of Ixazomib/Placebo to Lenalidomide in Patients With Evidence of Residual Multiple Myeloma, OPTIMUM Trial
Biospecimen Collection, Bone Marrow Aspirate, Bone Marrow Biopsy - Multiple Myeloma | Phase 3 | Completed | 1 | 2022-02-16 | 2025-05-23 |
A Study Comparing Daratumumab, VELCADE (Bortezomib), Lenalidomide, and Dexamethasone (D-VRd) With VELCADE, Lenalidomide, and Dexamethasone (VRd) in Participants With Untreated Multiple Myeloma and for Whom Hematopoietic Stem Cell Transplant is Not Planned as Initial Therapy
Daratumumab, Bortezomib, Lenalidomide - Multiple Myeloma | Phase 3 | Completed | 395 | 2018-11-06 | 2026-11-03 |
A Phase III Trial on the Effect of Elotuzumab in VRD Induction /Consolidation and Lenalidomide Maintenance in Patients With Newly Diagnosed Myeloma
elotuzumab, Lenalidomide, Bortezomib - Multiple Myeloma | Phase 3 | Completed | 564 | 2015-06-01 | 2021-09-10 |
Efficacy of Lenalidomide in Combination With Subcutaneous Rituximab + miniCHOP in DLBCL Patients of 80 y/o or+
Lenalidomide, Rituximab - Diffuse Large B Cell Lymphoma | Phase 3 | Completed | 250 | 2014-08-01 | 2021-04-13 |
R-CHOP + R-HAD vs R-CHOP Followed by Maintenance Lenalidomide + Rituximab vs Rituximab for Older Patients With MCL
R-CHOP, R-CHOP / R-HAD, Rituximab - Mantle Cell Lymphoma | Phase 3 | Completed | 623 | 2013-11-01 | 2025-03-05 |
A Study of Lenalidomide Maintenance for High-risk Patients With CLL Following First-line Therapy
lenalidomide, Placebo - Chronic Lymphocytic Leukemia | Phase 3 | Completed | 89 | 2012-07-20 | 2022-01-05 |
A Phase 3 Open Label Randomized Study to Compare the Efficacy and Safety of Rituximab Plus Lenalidomide (CC-5013) Versus Rituximab Plus Chemotherapy Followed by Rituximab in Subjects With Previously Untreated Follicular Lymphoma
Rituximab, Lenalidomide, Rituximab - CHOP - Follicular Lymphoma | Phase 3 | Completed | 1030 | 2012-02-01 | 2025-09-25 |
Combined Rituximab and Lenalidomide Treatment for Untreated Patients With Follicular Lymphoma
Rituximab, Lenalidomide, Rituximab-CHOP - Follicular Lymphoma | Phase 3 | Completed | 1030 | 2011-12-29 | 2025-05-14 |
Study Comparing Carfilzomib, Lenalidomide, and Dexamethasone (CRd) vs Lenalidomide and Dexamethasone (Rd) in Subjects With Relapsed Multiple Myeloma
Dexamethasone, Lenalidomide, Carfilzomib - Relapsed Multiple Myeloma | Phase 3 | Completed | 792 | 2010-07-14 | 2022-09-21 |
UARK 2009-09 Myeloma Cure Project: Prospective Trial of Indefinite Revlimid Maintenance Versus Observation for Currently Event-Free Patients With Multiple Myeloma
Revlimid - Multiple Myeloma | Phase 3 | Completed | 42 | 2010-04-01 | 2015-10-19 |
Combination of Lenalidomide and Dexamethasone in Treatment of Multiple Myeloma
Lenalidomide, Dexamethasone, Lenalidomide, Dexamethasone, PBSCT - Multiple Myeloma | Phase 3 | Completed | 348 | 2010-03-01 | 2023-02-23 |
A Study of Lenalidomide Versus Placebo in Subjects With Transfusion Dependent Anemia in Lower Risk Myelodysplastic Syndrome (MDS) Without Del 5q
Lenalidomide, Placebo - Anemia | Phase 3 | Completed | 239 | 2010-01-26 | 2019-06-25 |
Study to Evaluate Safety and Effectiveness of Lenalidomide in Combination With Docetaxel and Prednisone for Patients With Castrate-Resistant Prostate Cancer
Lenalidomide, Docetaxel, Prednisone - Prostate Cancer | Phase 3 | Completed | 1059 | 2009-11-11 | 2018-04-04 |
Study Of The Effectiveness & Safety Of Lenalidomide Versus Chlorambucil As First Line Therapy For Elderly Patients With B-Cell CLL (The ORIGIN Trial)
Lenalidomide, Chlorambucil - B-Cell Chronic Lymphocytic Leukemia | Phase 3 | Completed | 450 | 2009-10-13 | 2019-07-09 |
A Safety Confirmation Study on Lenalidomide With Dexamethasone In Japanese Patients With Previously Treated Multiple Myeloma
Lenalidomide, Dexamethasone - Multiple Myeloma | Phase 3 | Completed | 25 | 2009-04-28 | 2019-11-20 |
Study of Lenalidomide Maintenance Versus Placebo in Responding Elderly Patients With DLBCL and Treated With R-CHOP
Lenalidomide, Placebo - Lymphoma, Diffuse Large B-cell Lymphoma | Phase 3 | Completed | 650 | 2009-04-01 | 2021-07-26 |
Comparison of 25mg Versus 5 mg Lenalidomide as Maintenance Therapy in Patients With Multiple Myeloma
Lenalidomide - Multiple Myeloma | Phase 3 | Completed | 194 | 2009-04-01 | 2018-01-19 |
A Study to Evaluate the Efficacy and Safety of Lenalidomide as Maintenance Therapy for Patients With B-Cell Chronic Lymphocytic Leukemia (CLL) Following Second Line Therapy
Lenalidomide, Placebo - B-cell Chronic Lymphocytic Leukemia | Phase 3 | Completed | 317 | 2009-01-27 | 2021-12-02 |
Study to Determine Efficacy and Safety of Lenalidomide Plus Low-dose Dexamethasone Versus Melphalan, Prednisone, Thalidomide in Patients With Previously Untreated Multiple Myeloma
Lenalidomide and low-dose dexamethasone, Lenalidomide plus low-dose dexamethasone given for 18 four-week cycles, Melphalan, Prednisone and Thalidomide - Multiple Myeloma | Phase 3 | Completed | 1623 | 2008-08-21 | 2019-11-20 |
A Study to Compare MPR With MP in Newly Diagnosed Multiple Myeloma Subjects 65 Years Old or Older.
Lenalidomide: Double-blind Induction, Melphalan, Prednisone - Newly Diagnosed Multiple Myeloma | Phase 3 | Completed | 459 | 2007-01-01 | 2017-01-11 |
Showing 20 of 28. Sign in to see all of them.
Conditions studied
Multiple Myeloma (14) · Leukemia, Lymphocytic, Chronic, B-Cell (3) · Anemia (2) · Lymphoma, Follicular (2) · Lymphoma, Large B-Cell, Diffuse (2) · Myelodysplastic Syndromes (2) · Recurrence (2) · Back Pain (1) · Leukemia (1) · Low Back Pain (1) · Lymphoma (1) · Lymphoma, Mantle-Cell (1) · Neoplasms, Plasma Cell (1) · Prostatic Neoplasms (1) · Radiculopathy (1)
Sponsors
Celgene (10) · Celgene Corporation (5) · The Lymphoma Academic Research Organisation (4) · Gesellschaft fur Medizinische Innovation - Hamatologie und Onkologie mbH (2) · Amgen (1) · German CLL Study Group (1) · Janssen Research & Development, LLC (1) · National Cancer Institute (NCI) (1) · University Hospital, Toulouse (1) · University of Arkansas (1) · University of Heidelberg Medical Center (1)
Countries
France (15) · Germany (15) · Belgium (14) · Spain (14) · United States (13) · United Kingdom (11) · Australia (10) · Austria (10) · Canada (10) · Israel (10) · Italy (10) · Poland (10) · Netherlands (8) · Czechia (7) · Portugal (7)
Top investigators
Robert Knight, MD (5) · Franck Morschhauser, MD, PhD (2) · Albert Hoenekopp, MD (1) · Anna Fink, MD (1) · Antonio Palumbo, M.D. (1) · Barbara Eichhorst, MD (1) · Bart Barlogie, MD, PhD (1) · Christian Jacques, MD (1) · Christian Straka (1) · Debora Barton, MD (1) · Fabrice Jardin, MD,Professor (1) · Guido Kobbe, PD Dr. (1) · Hartmut Goldschmidt, Prof. Dr. (1)
Results publications
PMID 18799726, PMID 19901114, PMID 21273172, PMID 39374535, PMID 41915772, PMID 18032762, PMID 18032763, PMID 19332768, PMID 21109690, PMID 21753188, PMID 22292853, PMID 22571200, PMID 22571202, PMID 23242595, PMID 24682512, PMID 25482145, PMID 25743937, PMID 25840600, PMID 27354480, PMID 27550953, PMID 27560549, PMID 28106903, PMID 28140392, PMID 28373701, PMID 28651604, PMID 28916311, PMID 28958469, PMID 29322849, PMID 30184451, PMID 31138244, PMID 31978225, PMID 32064987, PMID 32673385, PMID 33278600, PMID 33512465, PMID 35710733, PMID 35947804, PMID 36740991, PMID 37990162, PMID 38194610, PMID 38302221, PMID 39536451, PMID 39910273, PMID 40499012, PMID 41056515, PMID 42234958, PMID 42789828
NIH funding
2005 (2), 2004 (1), 2008 (1), 2018 (1), 2023 (1), U10CA180820 (1)